Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B

Do Young Kim, Sang Hoon Ahn, Hyun Woong Lee, Jun Yong Park, Seung Up Kim, Yong Han Paik, Kwan Sik Lee, Kwang Hyub Han, Chae Yoon Chon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.

Original languageEnglish
Pages (from-to)293-298
Number of pages6
JournalIntervirology
Volume51
Issue number4
DOIs
Publication statusPublished - 2008 Nov 1

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Lamivudine
Mutation
Alanine Transaminase
Hepatitis B virus
DNA
Genotype

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

@article{11d3fef2d850403a8bf21fc2977dfd6f,
title = "Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B",
abstract = "Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.",
author = "Kim, {Do Young} and Ahn, {Sang Hoon} and Lee, {Hyun Woong} and Park, {Jun Yong} and Kim, {Seung Up} and Paik, {Yong Han} and Lee, {Kwan Sik} and Han, {Kwang Hyub} and Chon, {Chae Yoon}",
year = "2008",
month = "11",
day = "1",
doi = "10.1159/000170904",
language = "English",
volume = "51",
pages = "293--298",
journal = "Intervirology",
issn = "0300-5526",
publisher = "S. Karger AG",
number = "4",

}

Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. / Kim, Do Young; Ahn, Sang Hoon; Lee, Hyun Woong; Park, Jun Yong; Kim, Seung Up; Paik, Yong Han; Lee, Kwan Sik; Han, Kwang Hyub; Chon, Chae Yoon.

In: Intervirology, Vol. 51, No. 4, 01.11.2008, p. 293-298.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Lee, Hyun Woong

AU - Park, Jun Yong

AU - Kim, Seung Up

AU - Paik, Yong Han

AU - Lee, Kwan Sik

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.

AB - Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.

UR - http://www.scopus.com/inward/record.url?scp=55649118675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649118675&partnerID=8YFLogxK

U2 - 10.1159/000170904

DO - 10.1159/000170904

M3 - Article

C2 - 19001828

AN - SCOPUS:55649118675

VL - 51

SP - 293

EP - 298

JO - Intervirology

JF - Intervirology

SN - 0300-5526

IS - 4

ER -